Cancers & treatments·Regimen libraryLater line

Topotecan

Checked 2026-09-09

Relapsed SCLC; platinum-resistant ovarian or cervical cancer

One cycle

every 21 days

21-day cycle, until progressionIntravenous

Components

Drug	Dose	Route	Days	Note
Topotecan Cytotoxic (topoisomerase-I inhibitor)	1.5 mg/m² IV (or 2.3 mg/m² oral)	IV	D1-5

Cycles

until progression

21-day cycle

Emetogenicity

Low (10-30%)

G-CSF

Consider (10-20% FN risk)

Used in

Small-cell lung cancer Ovarian cancer Cervical cancer

Products

Source

NCCN Small Cell Lung Cancer; von Pawel, JCO 1999

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

Cisplatin + etoposide (EP)

Limited-stage SCLC with concurrent thoracic radiotherapy; stage III NSCLC chemoradiation; high-grade neuroendocrine carcinoma

every 21 days × 4

Carboplatin + etoposide + atezolizumab (or durvalumab)

Extensive-stage SCLC, first line

every 21 days × 4

Extensive-stage SCLC after platinum-based chemotherapy

Metastatic germ cell tumour: 3 cycles good risk, 4 cycles intermediate or poor risk

every 21 days × 3

Carboplatin + paclitaxel

Ovarian cancer adjuvant or neoadjuvant (6 cycles); advanced endometrial cancer with pembrolizumab or dostarlimab; NSCLC

every 21 days × 6

Carboplatin + paclitaxel + bevacizumab, then bevacizumab maintenance

Stage III-IV ovarian cancer, especially with residual disease or ascites

every 21 days × 6

Weekly paclitaxel

Platinum-resistant ovarian cancer (with or without bevacizumab); metastatic breast cancer

Pegylated liposomal doxorubicin

Platinum-resistant or partially platinum-sensitive ovarian cancer; Kaposi sarcoma

All regimens Tarlatamab →